Is Back on Investors’ Radar Pfizer (PFE) is attracting fresh attention after a period of mixed share performance, with the ...

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...

If you are wondering whether Pfizer's current share price offers value for what you are getting, this article breaks down the ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Pfizer PFE is set to release its fourth-quarter and full-year 2025 results on Feb. 3, with investor attention focused on ...

Pfizer is one of the world's largest pharmaceutical companies. Even after losing more than half of its value, it still has a ...

Pfizer's (NYSE:PFE) stock is up by 4.7% over the past three months. Given that the markets usually pay for the long-term ...

Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently ...

Pfizer Inc. shares currently offer a dividend yield approaching 7%, ranking among the highest in the S&P 500 index. While the upcoming ex-dividend date of January 23 presents an opportunity for income ...

Obesity is a growing problem that now has effective treatments. Pfizer has been eager to develop a strong position in this area. This acquisition gives Pfizer a viable obesity drug candidate. Pfizer's ...